What a Control-Based Asthma Management Strategy Looks Like

Program Overview

The introduction of biologics and updated understanding of asthma as a disease has changed our treatment approach to a more tailored, personalized strategy. This activity will take you through a pathophysiology-guided understanding of the various agents’ pharmacology. It will dive into a side-by-side exploration of safety and efficacy data for new and emerging treatments for asthma, reinforced by clinical case scenarios, expert commentary, interactive tools, and downloadable resources—all packaged and delivered in a visually impactful infographic design.

Credit Expired

Target Audience

The target audience for this activity is pulmonary and allergy/immunology providers including physicians, nurse practitioners, and physician assistants who manage patients with asthma.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Identify patients with poorly-controlled or difficult-to-treat asthma who are eligible for step-up therapies, including new and emerging biologics
  • Incorporate new and emerging targeted biologics into the management of patients with severe or poorly-controlled asthma, when appropriate

Activity Faculty

Reynold A. Panettieri, Jr, MD

Reynold A. Panettieri, Jr, MD

Vice Chancellor, Translational Medicine and Science
Director, Rutgers Institute for Translational Medicine and Science
Professor of Medicine, Rutgers University
New Brunswick, NJ
Emeritus Professor, Medicine
University of Pennsylvania
Philadelphia, PA


Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources